A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.

Eligibility

Inclusion Criteria:

* Voluntarily consent to participate in the study and sign the informed consent form
* Expected survival period \>12 weeks
* ECOG Performance Status 0 or 1
* Histologically confirmed unresectable locally advanced or metastatic --gastric/gastroesophageal junction adenocarcinoma
* No prior systemic therapy for locally advanced or metastatic gastric cancer; or disease progression or recurrence occurring ≥6 months after completion of neoadjuvant/adjuvant therapy
* HER2-high expression
* At least one assessable lesion according to RECIST v1.1 criteria
* Adequate organ function
* Female subjects of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first treatment, and agree not to breastfeed or donate ova from the signing of the informed consent form until 6 months after the last treatment. Male subjects must agree not to donate sperm from the signing of the informed consent form until 6 months after the last treatment.
* Able to understand the study requirements and willing to comply with the study and follow-up procedures

Exclusion Criteria:

* Presence of central nervous system (CNS) metastasis and/or carcinomatous meningitis
* Peripheral neuropathy \> Grade 1
* Tumor lesions with a tendency to bleed
* Severe gastrointestinal dysfunction that may affect drug intake, transport, or absorption
* Bone metastases with a risk of paraplegia
* Past or current interstitial lung disease, or severely impaired lung function
* Other malignancies within 5 years prior to randomization, except for those expected to be cured with treatment
* Pregnant or breastfeeding women

Conditions2

Interventions5

Related trials

• A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer — RemeGen Co., Ltd.
• Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients — Zhejiang Cancer Hospital
• Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Disitamab Vedotin (RC48-ADC) in Breast Cancer — RenJi Hospital
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer — Fudan University
• Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer — RemeGen Co., Ltd.
• First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) — Qilu Hospital of Shandong University

Browse More Trials